Implant manufacturer Centinel Spine has named Masson Spine Institute in Park City, Utah, as an investigational site for a two-level clinical trial investigating the treatment of symptomatic cervical disc disease.
The study will examine the safety and efficacy of Prodisc C in cervical disc injury, according to a December news release.
The trial aims to demonstrate that Prodisc C SK and Prodisc C Vivo are at least as safe and effective as Mobi-C — a similar cervical disc prosthesis on the market — to treat symptomatic cervical disc disease at two contiguous levels from C3 to C7.
Masson Spine Institute is now enrolling patients in the clinical trial.